Lu Lu

List of Publications by Citations

215 papers	8,463 citations	42 h-index	86 g-index
240 ext. papers	11,507 ext. citations	10.8 avg, IF	6.56 L-index

#	Paper	IF	Citations
215	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerging Microbes and Infections*, **2020**, 9, 382-385	18.9	862
214	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Research*, **2020**, 30, 343-355	24.7	745
213	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cellular and Molecular Immunology*, **2020**, 17, 765-767	15.4	382
212	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications		282
211	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Science Advances*, **2019**, 5, eaav4580	14.3	268
210	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nature Communications*, **2014**, 5, 3067	17.4	247
209	Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. *Cell*, **2021**, 184, 92-105.e16	38.6	240
208	Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. *Journal of Virology*, **2014**, 88, 7796-805	6.6	182
207	MERS-CoV spike protein: a key target for antivirals. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 131-143	6.4	176
206	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. *Signal Transduction and Targeted Therapy*, **2020**, 5, 92	21	170
205	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. *Cell Research*, **2021**, 31, 126-140	24.7	165
204	Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host and Microbe*, **2020**, 27, 891-898.e5	23.4	155
203	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. *JAMA Internal Medicine*, **2020**, 180, 1356-1362	11.5	152
202	Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. *Journal of Virology*, **2013**, 87, 9939-42	6.6	140
201	Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. *Science*, **2020**, 367,	33.3	105
200	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. *Cellular and Molecular Immunology*, **2016**, 13, 180-90	15.4	96
199	Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.. *Clinical Infectious Diseases*, **2021**,	11.6	94

198	AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling. *Nature Microbiology*, **2018**, 3, 302-309	26.6	92
197	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. *Cellular and Molecular Immunology*, **2020**, 17, 554	15.4	91
196	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27141-27147	11.5	91
195	High neutralizing antibody titer in intensive care unit patients with COVID-19. *Emerging Microbes and Infections*, **2020**, 9, 1664-1670	18.9	86
194	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. *Nature Communications*, **2017**, 8, 15672	17.4	83
193	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. *Virus Research*, **2014**, 194, 200-10	6.4	79
192	SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells.. *Emerging Microbes and Infections*, **2021**, 1-18	18.9	75
191	Additional molecular testing of saliva specimens improves the detection of respiratory viruses. *Emerging Microbes and Infections*, **2017**, 6, e49	18.9	73
190	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. *Journal of Infectious Diseases*, **2015**, 212, 1894-903	7	71
189	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. *Signal Transduction and Targeted Therapy*, **2020**, 5, 282	21	71
188	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.. *Nature*, **2022**,	50.4	70
187	Genomic signature and protein sequence analysis of a novel influenza A□(H7N9) virus that causes an outbreak in humans in China. *Microbes and Infection*, **2013**, 15, 432-9	9.3	67
186	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. *Journal of Virology*, **2016**, 90, 57-67	6.6	64
185	Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. *Journal of Medicinal Chemistry*, **2011**, 54, 572-9	8.3	63
184	Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in□identifying its source and controlling its spread. *Microbes and Infection*, **2013**, 15, 625-9	9.3	59
183	Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. *Lancet Microbe, The*, **2020**, 1, e111-e118	22.2	56
182	Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. *Cellular and Molecular Immunology*, **2020**, 17, 894	15.4	56
181	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. *Cell Reports*, **2021**, 34, 108699	10.6	54

180	Respiratory syncytial virus entry inhibitors targeting the F protein. *Viruses*, **2013**, 5, 211-25	6.2	52
179	Receptor-binding domain-based subunit vaccines against MERS-CoV. *Virus Research*, **2015**, 202, 151-9	6.4	49
178	A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. *Retrovirology*, **2012**, 9, 104	3.6	49
177	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. *Current Topics in Medicinal Chemistry*, **2016**, 16, 1074-90	3	49
176	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	46
175	Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. *Journal of Biological Chemistry*, **2010**, 285, 25506-15	5.4	43
174	In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. *Journal of Biological Chemistry*, **2011**, 286, 3277-87	5.4	41
173	Receptor-binding domain as a target for developing SARS vaccines. *Journal of Thoracic Disease*, **2013**, 5 Suppl 2, S142-8	2.6	41
172	Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus Infection. *EBioMedicine*, **2017**, 20, 193-201	8.8	40
171	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. *Nature Communications*, **2021**, 12, 866	17.4	40
170	Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. *Viruses*, **2013**, 5, 127-49	6.2	39
169	Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. *Journal of Biological Chemistry*, **2007**, 282, 6143-52	5.4	39
168	Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. *Journal of Biological Chemistry*, **2008**, 283, 16723-31	5.4	37
167	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. *Cell Host and Microbe*, **2017**, 22, 471-483.e5	23.4	36
166	Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. *Cell Research*, **2021**, 31, 98-100	24.7	35
165	Development of therapeutics for treatment of Ebola virus infection. *Microbes and Infection*, **2015**, 17, 109-17	9.3	34
164	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. *Journal of Infection*, **2013**, 66, 464-6	18.9	34
163	Emerging SARS-CoV-2 variants expand species tropism to murines. *EBioMedicine*, **2021**, 73, 103643	8.8	34

162	Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 742-4	5.9	33
161	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. *Emerging Microbes and Infections*, **2017**, 6, e89	18.9	33
160	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. *Emerging Microbes and Infections*, **2012**, 1, e13	18.9	33
159	Advancements in the development of subunit influenza vaccines. *Microbes and Infection*, **2015**, 17, 123-34	3.3	30
158	Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. *PLoS ONE*, **2013**, 8, e59777	3.7	30
157	HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. *PLoS ONE*, **2011**, 6, e18233	3.7	30
156	Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. *Journal of Medicinal Chemistry*, **2014**, 57, 7342-54	8.3	29
155	An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2533-44	5.1	29
154	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. *Microbes and Infection*, **2015**, 17, 142-8	9.3	28
153	Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. *Clinical Infectious Diseases*, **2021**,	11.6	28
152	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. *Protein and Cell*, **2018**, 9, 596-615	7.2	26
151	Zika virus infects renal proximal tubular epithelial cells with prolonged persistency and cytopathic effects. *Emerging Microbes and Infections*, **2017**, 6, e77	18.9	26
150	HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. *Biochimica Et Biophysica Acta - Biomembranes*, **2012**, 1818, 2950-7	3.8	26
149	The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. *PLoS ONE*, **2012**, 7, e37019	3.7	26
148	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. *Scientific Reports*, **2015**, 5, 13028	4.9	25
147	A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. *Aids*, **2017**, 31, 885-894	3.5	24
146	Antivirals with common targets against highly pathogenic viruses. *Cell*, **2021**, 184, 1604-1620	56.2	24
145	Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. *Aids*, **2016**, 30, 827-38	3.5	24

144	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	23
143	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. *Journal of Virology*, **2017**, 91,	6.6	23
142	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. *BioMed Research International*, **2017**, 2017, 6096134	3	23
141	Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 7539-48	3.4	23
140	Using gene expression databases for classical trait QTL candidate gene discovery in the BXD recombinant inbred genetic reference population: mouse forebrain weight. *BMC Genomics*, **2008**, 9, 444	4.5	23
139	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. *Biochimica Et Biophysica Acta - Biomembranes*, **2014**, 1838, 1296-305	3.8	22
138	Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 67, 1-6	3.1	22
137	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. *Emerging Microbes and Infections*, **2016**, 5, e65	18.9	22
136	Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. *Journal of Virology*, **2012**, 86, 589-93	6.6	21
135	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. *Viruses*, **2019**, 11,	6.2	20
134	Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 2527-39	8.3	20
133	Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. *Retrovirology*, **2010**, 7, 37	3.6	20
132	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. *Viruses*, **2019**, 11,	6.2	20
131	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 707-719	6.8	19
130	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. *Frontiers in Microbiology*, **2020**, 11, 1063	5.7	19
129	Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction. *World Journal of Gastroenterology*, **2015**, 21, 4852-63	5.6	19
128	HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. *Laboratory Investigation*, **2014**, 94, 777-87	5.9	19
127	Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis		19

126	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. *Frontiers in Microbiology*, **2018**, 9, 2643	5.7	18
125	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. *Emerging Microbes and Infections*, **2017**, 6, e59	18.9	17
124	Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection. *FEBS Letters*, **2014**, 588, 1515-22	3.8	17
123	Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3284-6	2.9	17
122	PA-356R is a unique signature of the avian influenza A (H7N9) viruses with bird-to-human transmissibility: potential implication for animal surveillances. *Journal of Infection*, **2013**, 67, 490-4	18.9	17
121	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. *Virologica Sinica*, **2020**, 35, 857-860	6.4	17
120	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. *Signal Transduction and Targeted Therapy*, **2021**, 6, 132	21	17
119	Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity. *Biochemical and Biophysical Research Communications*, **2019**, 508, 1018-1023	3.4	17
118	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. *Frontiers of Medicine*, **2017**, 11, 449-461	12	16
117	Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. *Journal of Virology*, **2010**, 84, 9359-68	6.6	16
116	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. *EBioMedicine*, **2021**, 71, 103544	8.8	16
115	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
114	Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. *Journal of Virology*, **2015**, 89, 6960-4	6.6	15
113	ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5123-34	5.9	15
112	Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. *Microbes and Infection*, **2013**, 15, 506-10	9.3	15
111	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. *Molecules*, **2019**, 24,	4.8	14
110	Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. *Chemical Communications*, **2012**, 48, 11579-81	5.8	14
109	Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. *Clinical Infectious Diseases*, **2013**, 57, 919-21	11.6	14

108	A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. *Current Pharmaceutical Design*, **2015**, 21, 925-35	3.3	14
107	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. *Viruses*, **2019**, 11,	6.2	14
106	Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. *Microbes and Infection*, **2018**, 20, 626-634	9.3	14
105	A tailored extracellular matrix (ECM) - Mimetic coating for cardiovascular stents by stepwise assembly of hyaluronic acid and recombinant human type III collagen. *Biomaterials*, **2021**, 276, 121055	15.6	14
104	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. *Protein and Cell*, **2021**, 12, 84-88	7.2	14
103	Development of oncolytic virotherapy: from genetic modification to combination therapy. *Frontiers of Medicine*, **2020**, 14, 160-184	12	13
102	Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China. *Virology Journal*, **2013**, 10, 10	6.1	13
101	Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. *Aids*, **2014**, 28, 1251-60	3.5	13
100	A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. *Journal of Biological Chemistry*, **2011**, 286, 28425-34	5.4	13
99	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 288	21	13
98	Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1537-45	5.1	12
97	The cytoplasmic domain of influenza M2 protein interacts with caveolin-1. *Archives of Biochemistry and Biophysics*, **2009**, 486, 150-4	4.1	12
96	Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. *Aids*, **2019**, 33, 1545-1555	3.5	12
95	Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations. *Scientific Reports*, **2016**, 6, 31983	4.9	11
94	Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. *Molecules*, **2017**, 22,	4.8	11
93	Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. *Microbes and Infection*, **2017**, 19, 597-604	9.3	10
92	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.. *Cell Research*, **2022**,	24.7	10
91	Fully human single-domain antibodies against SARS-CoV-2		10

90	A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. *Microbes and Infection*, **2016**, 18, 148-52	9.3	10
89	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. *Cellular and Molecular Immunology*, **2019**, 16, 757-769	15.4	9
88	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). *Emerging Microbes and Infections*, **2015**, 4, e37	18.9	9
87	3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 573-6	5.1	9
86	Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2011**, 56, 384-92	3.1	9
85	Important changes in biochemical properties and function of mutated LLP12 domain of HIV-1 gp41. *Chemical Biology and Drug Design*, **2007**, 70, 311-8	2.9	9
84	Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.. *Emerging Microbes and Infections*, **2022**, 1-17	18.9	9
83	design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. *Chemical Science*, **2015**, 6, 6505-6509	9.4	8
82	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. *Virologica Sinica*, **2020**, 35, 340-343	6.4	8
81	Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. *Scientific Reports*, **2016**, 6, 32161	4.9	8
80	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.. *Vaccines*, **2021**, 9,	5.3	8
79	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). *Cell Discovery*, **2021**, 7, 109	22.3	8
78	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. *Aids*, **2018**, 32, 1749-1761	3.5	8
77	Rhinovirus respiratory tract infection in hospitalized adult patients is associated with T2 response irrespective of asthma. *Journal of Infection*, **2018**, 76, 465-474	18.9	7
76	A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. *European Journal of Pharmaceutical Sciences*, **2018**, 117, 313-320	5.1	7
75	A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. *Amino Acids*, **2016**, 48, 2867-2873	3.5	7
74	HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. *Journal of Biological Chemistry*, **2011**, 286, 44869-77	5.4	7
73	V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. *Vaccine*, **2008**, 26, 845-52	4.1	7

72	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. *Emerging Microbes and Infections*, **2016**, 5, e41	18.9	7
71	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. *PLoS Pathogens*, **2019**, 15, e1008082	7.6	7
70	Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo. *Immunity*, **2021**, 54, 2231-2244.e6	32.3	7
69	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. *Journal of Infection*, **2017**, 75, 68-71	18.9	6
68	Assessment of population susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging influenza virus strains. *Epidemiology and Infection*, **2019**, 147, e279	4.3	6
67	Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K Channel Integrity. *Journal of Immunology*, **2019**, 202, 3187-3197	5.3	6
66	Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. *Viruses*, **2015**, 7, 798-819	6.2	6
65	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. *ACS Infectious Diseases*, **2020**, 6, 882-890	5.5	6
64	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3719-23	2.9	6
63	Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. *Journal of Infection*, **2013**, 67, 156-8	18.9	6
62	Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. *PLoS ONE*, **2013**, 8, e66156	3.7	6
61	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.. *Cell Research*, **2022**,	24.7	6
60	Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. *Journal of Medical Virology*, **2016**, 88, 1098-101	19.7	6
59	Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. *Viruses*, **2019**, 11,	6.2	6
58	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.. *Cell*, **2022**,	56.2	6
57	Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. *Microbes and Infection*, **2015**, 17, 135-41	9.3	5
56	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. *Science Translational Medicine*, **2020**, 12,	17.5	5
55	Design, modeling and 3D printing of a personalized cervix tissue implant with protein release function. *Biomedical Materials (Bristol)*, **2020**, 15, 045005	3.5	5

54	An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. *Chemical Science*, **2016**, 7, 2145-2150	9.4	5
53	A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue. *Frontiers in Microbiology*, **2019**, 10, 2250	5.7	5
52	Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodies. *Journal of Infectious Diseases*, **2013**, 208, 1315-9	7	5
51	The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry. *PLoS ONE*, **2012**, 7, e44874	3.7	5
50	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. *Signal Transduction and Targeted Therapy*, **2021**, 6, 378	21	5
49	Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds. *Journal of Materials Chemistry B*, **2021**, 9, 9684-9699	7.3	5
48	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
47	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. *Frontiers in Microbiology*, **2018**, 9, 2570	5.7	5
46	Design and Biological Evaluation of -Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. *Journal of Medicinal Chemistry*, **2019**, 62, 8773-8783	8.3	4
45	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. *Journal of Virology*, **2019**, 93,	6.6	4
44	Receptor binding domain based HIV vaccines. *BioMed Research International*, **2015**, 2015, 594109	3	4
43	Biosecurity and biosafety in research on emerging pathogens. *Emerging Microbes and Infections*, **2012**, 1, e44	18.9	4
42	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.. *Vaccines*, **2022**, 10,	5.3	4
41	Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion		4
40	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	4
39	A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. *Viruses*, **2019**, 11,	6.2	3
38	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. *Lancet, The*, **2015**, 386, S44	40	3
37	F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. *Microbes and Infection*, **2013**, 15, 887-94	9.3	3

36	Dissolving microneedle-encapsulated drug-loaded nanoparticles and recombinant humanized collagen type III for the treatment of chronic wound anti-inflammation and enhanced cell proliferation and angiogenesis.. *Nanoscale*, **2022**,	7.7	3
35	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. *Molecules*, **2021**, 26,	4.8	3
34	Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. *Frontiers in Pharmacology*, **2020**, 11, 613361	5.6	3
33	Tactics used by HIV-1 to evade host innate, adaptive, and intrinsic immunities. *Chinese Medical Journal*, **2013**, 126, 2374-9	2.9	3
32	A genome-scale screen for synthetic drivers of T cell proliferation.. *Nature*, **2022**, 603, 728-735	50.4	3
31	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.. *EBioMedicine*, **2022**, 79, 103986	8.8	3
30	Injectable multifunctional hyaluronic acid/methylcellulose hydrogels for chronic wounds repairing.. *Carbohydrate Polymers*, **2022**, 289, 119456	10.3	3
29	Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. *Cellular and Molecular Immunology*, **2017**, 14, 568-571	15.4	2
28	Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. *Vaccines*, **2020**, 8,	5.3	2
27	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. *Emerging Microbes and Infections*, **2017**, 6, e102	18.9	2
26	Poly(U) and CpG ameliorate the unbalanced T cell immunity and pneumonia of mice with RSV vaccine-enhanced disease. *BioScience Trends*, **2017**, 11, 450-459	9.9	2
25	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody		2
24	Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant.. *Diagnostics*, **2021**, 11,	3.8	2
23	Engineered Trimeric ACE2 Binds and Locks Three-up Spike Protein to Potently Inhibit SARS-CoVs and Mutants		2
22	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. *Cell and Bioscience*, **2021**, 11, 128	9.8	2
21	A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. *Journal of Medicinal Chemistry*, **2021**, 64, 11460-11471	8.3	2
20	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 318	21	2
19	An ultrapotent pan-coronavirus lineage B (CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. *Protein and Cell*, **2021**, 1	7.2	2

18	A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant.. *Cell Research*, **2022**,	24.7	2
17	Interferon-gamma inhibits influenza A virus cellular attachment by reducing sialic acid cluster size.. *IScience*, **2022**, 25, 104037	6.1	2
16	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.. *Vaccines*, **2022**, 10,	5.3	1
15	Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in mouse model.. *Emerging Microbes and Infections*, **2022**, 1-36	18.9	1
14	Microfibrillated cellulose-enhanced carboxymethyl chitosan/oxidized starch sponge for chronic diabetic wound repair.. *Materials Science and Engineering C*, **2022**, 112669	8.3	1
13	High compliance to infection control measures prevented guest-to-staff transmission in COVID-19 quarantine hotels. *Journal of Infection*, **2021**,	18.9	1
12	Immunoengineered adjuvants for universal vaccines against respiratory viruses. *Fundamental Research*, **2021**, 1, 189-192		1
11	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human Coronavirus Infection. *Journal of Medicinal Chemistry*, **2021**,	8.3	1
10	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. *Microbes and Infection* , **2021**, 23, 104840	9.3	1
9	Coronavirus Entry Inhibitors.. *Advances in Experimental Medicine and Biology*, **2022**, 1366, 101-121	3.6	1
8	Long-acting Protective Ocular Surface by Instilling Adhesive Dual-antiviral Nanoparticles.. *Advanced Healthcare Materials*, **2022**, e2200283	10.1	1
7	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells.. *MBio*, **2022**, e0338421	7.8	0
6	Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.. *MSphere*, **2022**, e0091521	5	0
5	Normal human sera contain heat-sensitive factor(s) to enhance H7N9 influenza virus infection. *Journal of Infection*, **2016**, 72, 123-5	18.9	
4	An artificial peptide-based HIV-1 fusion inhibitor containing M-T hook structure exhibiting improved antiviral potency and drug resistance profile. *Future Virology*, **2015**, 10, 961-969	2.4	
3	The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: Involvement in viral fusion. *Science Bulletin*, **2009**, 54, 1707-1712	10.6	
2	Intra-amniotic Injection of Mouse Embryos. *Bio-protocol*, **2018**, 8, e2854	0.9	
1	Design of artificial helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114336	6.8	